We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Corvidia Therapeutics

News List

Apple Tree Partners Portfolio Company Corvidia Therapeutics to be Acquired by Novo Nordisk americanpharmaceuticalreview
June 23, 2020
Apple Tree Partners (ATP) will exit its ownership stake in Corvidia Therapeutics, a precision cardiovascular therapeutics company, with Novo Nordisk’s acquisition of Corvidia.
Novo snaps up cardio-renal group Corvidia pharmatimes
June 16, 2020
Novo Nordisk has signed a deal to acquire Corvidia Therapeutics, a privately held, clinical stage company with a focus on the research and development of transformative therapies for cardio-renal diseases.
Novo Nordisk to acquire Corvidia Therapeutics for $725m pharmaceutical-technology
June 15, 2020
Danish healthcare company Novo Nordisk has signed a definitive agreement to acquire US-based Corvidia Therapeutics, which develops and commercialises therapies for cardio-renal diseases, for an upfront payment of $725m.
Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work biospace
April 26, 2018
Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round.